<DOC>
	<DOCNO>NCT01995513</DOCNO>
	<brief_summary>The purpose study determine continue treatment Enzalutamide effective patient metastatic prostate cancer .</brief_summary>
	<brief_title>Safety Study Continued Enzalutamide Treatment In Prostate Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Men metastatic castrationresistant prostate cancer Progressive disease androgen deprivation therapy Patients must agree continue androgen deprivation therapy GnRH agonist/antagonist throughout study prior bilateral orchiectomy ECOG performance score ≤ 1 Estimated life expectancy ≥ 12 month Prior cytotoxic chemotherapy , aminoglutethimide , ketoconazole , abiraterone , enzalutamide treatment prostate cancer Prior participation clinical trial investigational agent inhibits androgen receptor androgen synthesis ( unless treatment placebo ) History brain metastasis , active leptomeningeal disease seizure Severe cardiovascular hepatic disease Pituitary adrenal dysfunction</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>